Palladone (Hydromorphone Hydrochloride)

Hydromorphone binds to μ‑opioid receptors in the brain and spinal cord, decreasing the release of neurotransmitters that transmit pain signals. This receptor activation reduces the perception of pain and can produce sedation and respiratory effects.

The appropriate dose of Palladone is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and overall clinical condition. Dosing regimens are individualized and should follow local prescribing guidelines.

Hydromorphone is classified as a pregnancy‑category C medication in many regions and can cross the placenta. It may cause neonatal respiratory depression and is excreted in breast milk. Use only if the potential benefit justifies the potential risk, and under close medical supervision.

To order Palladone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hydromorphone is more potent on a milligram‑per‑milligram basis than morphine, offering stronger analgesia with a shorter onset. Compared with oxycodone, it has a similar potency but may present a different side‑effect profile, requiring individualized selection based on patient response and tolerability.

Palladone should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and dispose of any unused medication according to local regulations.

Palladoin is typically administered orally in tablet or liquid form, as directed by the prescriber. The medication should be taken with or without food, according to the specific product instructions, and patients should follow the dosing schedule provided by their healthcare professional.

The most serious risks include respiratory depression, severe hypotension, profound sedation, dependence, and the potential for overdose. Patients should be monitored closely for signs of respiratory compromise and educated on safe use, especially when combined with other central nervous system depressants.

Palladone is contraindicated in individuals with known hypersensitivity to hydromorphone or other opioids, patients with significant respiratory depression, acute or severe asthma, and those who have taken monoamine oxidase inhibitors within the past 14 days.